WilmerHale Advises GentiBio in $157M Series A Funding
On August 11, 2021, GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, announced it has closed a Series A financing generating immediate proceeds of $157 million, led by Matrix Capital Management with by Avidity Partners, JDRF T1D Fund, seed investors OrbiMed, RA Capital Management, Novartis Venture Fund and Seattle Children’s Research Institute. The company’s unique platform aspires to functionally cure autoimmune, alloimmune, autoinflammatory and allergic diseases using novel technologies that precisely redirect stable, potent engineered Tregs to tissues damaged by abnormal immune responses. GentiBio has raised more than $177 million since 2020 to transcend technical hurdles that have limited the potential of therapeutic Tregs. The Series A financing will enable GentiBio to advance its potential functional cure for Type 1 Diabetes to the clinic alongside multiple other programs in chronic autoimmunity and autoinflammation.
The WilmerHale team advising GentiBio consisted of Jason Kropp, Mark Nylen and Jahnvi Desai.